Publikationen in Zusammenarbeit mit Forschern von University Hospital Aachen (57)

2024

  1. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial

    Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257

  2. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  3. Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 1, pp. 93-103

  4. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  5. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029

2023

  1. Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study

    Intensive Care Medicine, Vol. 49, Núm. 12, pp. 1441-1455

  2. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  3. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  2. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  3. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria

    Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901

  4. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  5. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  6. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2021

  1. Abnormal liver function test in patients infected with coronavirus (Sars-cov-2): A retrospective single-center study from spain

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-18

  2. An Experimental DUAL Model of Advanced Liver Damage

    Hepatology Communications, Vol. 5, Núm. 6, pp. 1051-1068

  3. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  4. EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI): Study protocol for a multicentre, observational trial

    BMJ Open, Vol. 11, Núm. 12

  5. Fibrotic events in the progression of cholestatic liver disease

    Cells, Vol. 10, Núm. 5

  6. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382